Key Developments: Virbac SA (VIRB.PA)

VIRB.PA on Paris Stock Exchange

4 May 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Virbac proposes stable FY 2014 dividend
Friday, 24 Apr 2015 11:12am EDT 

Virbac SA:Proposes stable FY 2014 dividend of 1.90 euros per share.  Full Article

Virbac closes Sentinel brands family acquisition Eli Lilly
Monday, 5 Jan 2015 02:28am EST 

Virbac SA:Announces closing of Sentinel brands family acquisition in United States from Eli Lilly.Acquisition closed on Jan. 2.  Full Article

Nexvet Biopharma Pty Ltd announces collaboration and distribution agreement with Virbac SA
Wednesday, 3 Dec 2014 05:30am EST 

Nexvet Biopharma Pty Ltd:Says signing of a ten year collaboration and distribution agreement with Virbac SA.Virbac will distribute NV-01, Nexvet's product, in territories outside the U.S. and Canada. NV-01 is an anti-nerve growth factor monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in dogs.  Full Article

Virbac to acquire United States veterinary assets from Eli Lilly
Monday, 27 Oct 2014 02:33am EDT 

Virbac SA:Agrees to acquire veterinary assets from Eli Lilly in United States.Says deal is for veterinary products marketed by Novartis Animal Health.Says assets to be acquired are related to two parasiticides for dogs, namely Sentinel Flavor Tabs and Sentinel Spectrum.Says deal is subject to approval by Federal Trade Commission and conditioned on closing of acquisition of Novartis Animal Health by Eli Lilly.  Full Article

Virbac to propose terms of share repurchase program
Thursday, 22 May 2014 11:21am EDT 

Virbac SA:To propose terms of share repurchase program to annual general meeting on June 17.Taking into account shares already held by company, program would authorize repurchase of up to 816,298 shares, or 9.7 pct of share capital.Maximum price per share 300 euros.Total maximum that could be spent 244,889,400 euros.Authorization valid for 18 months.  Full Article

Virbac proposes FY 2013 dividend
Wednesday, 19 Mar 2014 12:45pm EDT 

Virbac SA:Proposes unchanged FY 2013 dividend of 1.90 euro per share, paybale on June 25.  Full Article

Virbac SA Announces Details of Share Repurchase Program
Tuesday, 4 Jun 2013 03:28am EDT 

Virbac SA announced details of the share repurchase program which will be submitted for the approval of its Annual General Meeting on June 17, 2013. The Company currently holds 29,695 of its own shares, that is 0.35% of the share capital. The Company may repurchase a maximum of 10% of its, share capital. Taking into account the shares already held by the Company, the maximum number of shares which may be repurchased as part of the program is 816,105. The maximum price per share is EUR 250, and the total maximum which may be spent on the program is EUR 204,026,250. If approved, the program will run for a period of 18 months.  Full Article

NovaBay Pharmaceuticals Inc And Virbac SA Enter Into Collaboration And License Agreement For Animal Health
Tuesday, 28 May 2013 03:05am EDT 

NovaBay Pharmaceuticals Inc announced that it has entered into a collaboration and license agreement with Virbac SA, a global veterinary product company. Virbac exercised its March 2012 Feasibility and Option Agreement, thereby acquiring exclusive worldwide rights to develop NovaBay's compound, auriclosene (NVC-422), for global veterinary markets. NovaBay will receive an option exercise fee as well as development and pre-commercial payments as a result of the collaboration. NovaBay also expects to receive royalties on the sale of any commercial products in the companion animal field. Virbac's option exercise follows its testing of auriclosene for veterinary uses during the 12-month option period.  Full Article

BRIEF-Virbac sales growth of 17.1 pct in Q1 2015

* Q1 sales 211.4 million euros ($224.1 million), up 17.1 percent versus year ago

Search Stocks